Merck-Acceleron Deal Would Come With Side Effects

Merck is in some ways a victim of its own success. Its cancer treatment, Keytruda, represents a growing percentage and already over a third of revenue at the $185 billion pharmaceutical company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.